Loading
A phase 2 trial of Nivolumab in hepatocellular carcinoma, run by Teclison Ltd., now recruiting.
Combination of TATE and PD-1 Inhibitor in Liver Cancer is a phase 2 interventional study registered as NCT03259867 by Teclison Ltd., with 54 participants planned, started 2017-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization. Conditions listed: Hepatocellular Carcinoma, Gastric Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/